Journal article

ETOPOSIDE IN ACUTE NONLYMPHOCYTIC LEUKEMIA

JF BISHOP, RM LOWENTHAL, D JOSHUA, JP MATTHEWS, D TODD, R COBCROFT, MG WHITESIDE, H KRONENBERG, D MA, A DODDS, R HERRMANN, J SZER, MM WOLF, G YOUNG

Blood | AMER SOC HEMATOLOGY | Published : 1990

Abstract

Previously untreated patients with acute nonlymphocytic leukemia (ANLL) aged 15 to 70 years were randomized to either cytosine arabinoside 100 mg/m2/d continuous intravenous (IV) infusion days 1 through 7, daunorubicin 50 mg/m2/d IV days 1 through 3 (7-3), or the same drugs intensified with etoposide 75 mg/m2/d IV days 1 through 7 (7-3-7) as induction therapy. Patients achieving complete remission (CR) received two courses of consolidation therapy (5-2 or 5-2-5) followed by maintenance therapy. Of 264 eligible patients, CR occurred in 56% of 7-3 and 59% of 7-3-7 patients; 7-3-7 significantly improved remission duration (P = .01). The median remission duration was 12 months for 7-3 and 18 mon..

View full abstract